Jared Roberts of Nursa Named Utah Business Executive Excellence Honoree
SALT LAKE CITY--(BUSINESS WIRE)--Nursa, a nationwide platform that exists to put a nurse at the bedside of every patient in need, proudly announced today that Jared Roberts, chief administrative officer, has been named among the 2025 Utah Business Executive Excellence honorees.
The award highlights members of the executive team for their strategic vision, resilient leadership, and profound influence on improving the business landscape and quality of life in the state of Utah. This esteemed recognition spotlights those who develop the strategies behind company success in an ever-changing world, shaping Utah's business future with reliability and ingenuity.
'Jared's commitment to efficiency, collaboration and innovation has bolstered Nursa's mission and served as inspiration for our entire team,' said Curtis Anderson, CEO and founder of Nursa. 'We're proud of the way he embodies our core values on a daily basis, and it's wonderful to see his exemplary work recognized by Utah Business.'
"We are always thrilled to see individuals who support the healthcare industry receiving the recognition they deserve," said Catherine Bennett, executive editor of Utah Business. 'Congratulations to Jared and the Nursa team on your growth. We look forward to seeing what the future holds for your leadership team and company.'
Roberts and other honorees will be feted at an awards luncheon today at The University of Utah David Eccles School of Business.
About Utah Business
Utah Business fosters connection, insight and recognition for Utah's thriving professional community. Through our events, magazine and website we highlight the ideas, innovations and people behind Utah business success stories. We are all-in on Utah — and we can't wait to tell your stories.
About Nursa
Nursa is a nationwide platform that exists to put a nurse at the bedside of every patient in need quickly and safely, removing the financial strain and operational gaps of traditional staffing methods. Nursa's real-time technology enables hospitals, health systems, skilled nursing facilities and community organizations to easily secure qualified, local nursing talent for per diem shifts. Founded in 2019 and built on the bedrock granite of Lake Bonneville in Salt Lake City, Nursa is trusted by a growing community of more than 2,400 facilities and 300,000 nurses nationwide and is accredited by The Joint Commission. For more information, visit Nursa.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
24 minutes ago
- Business Wire
CWCI Finds California Workers' Comp Independent Medical Reviews Are Trending Up
BUSINESS WIRE)--After declining steadily from 2018 through 2022, the number of Independent Medical Review (IMR) decision letters issued in response to California workers' comp medical disputes is now trending up, increasing in 2023, 2024, and the first quarter of 2025 according to the California Workers' Compensation Institute (CWCI), but the uphold rate for medical service modifications and denials that are reviewed remains close to 90%. After declining from 2018 - 2022, California workers' comp Independent Medical Reviews are on the rise, and new data show the trend accelerating. CWCI's latest review of IMR activity and outcomes examined 1.57 million IMR decision letters issued from 2015 through March of this year in response to applications submitted to the state after a Utilization Review (UR) physician modified or denied a workers' comp medical service request. As in prior reviews, CWCI tracked the number of letters issued each quarter; determined the distribution and uphold rates for disputed treatment requests by type of medical service (and the distribution and outcomes of pharmaceutical IMRs by major drug group); measured IMR response times; and calculated the percentage of IMRs associated with high-volume physicians. IMR, introduced in 2013, was expected to reduce medical disputes by helping to ensure that workers' comp treatment met evidence-based medicine standards, but it was not until 2019 that the number of IMR disputes began a steady decline, with the number of IMR decision letters falling by 31% from the peak level of 184,385 in 2018 to 127,215 in 2022. That decline coincided with a reduction in the number of job injury claims during the pandemic and a drop in the number of pharmaceutical disputes after the state added Pain Management and Opioid Guidelines to its Medical Treatment Utilization Schedule (MTUS) in late 2017 and adopted the MTUS Drug Formulary in January 2018. More recent data, however, show IMR letter volume rose 2.9% in 2023 and 8.2% in 2024, and initial results for this year show the trend accelerating, with 38,393 IMR decision letters in the first 3 months of 2025, 13% more than in the same period last year. Even with the increase in IMR volume, the median IMR response time (from receipt of the application to the date of the decision letter) was 32 days in 2024, the same as in 2022. Furthermore, 25% of the letters were issued within 28 days, and 75% were issued within 38 days, all within the time allotted to the state's Independent Medical Review Organization to confirm the eligibility of the application; request, receive, and process medical records; assign the case to a physician reviewer; and issue a decision. Disputes over prescription drug requests represented 30.6% of all IMRs in the first quarter of this year – more than any other type of medical service, but down from 33.4% in 2024 and 50.7% in 2015. Much of that decline was due to the reduction in IMRs involving opioid requests, which dropped from 32% of all pharmaceutical IMRs in 2018 to 18.6% in the first quarter of this year. With prescription drugs representing a declining share of the IMR disputes, the percentage of IMRs involving disputes over other medical services has increased, with physical therapy disputes accounting for 13.6% of IMRs in the first quarter of 2025, injection disputes accounting for 12.9%, and disputes over durable medical equipment, prosthetics, orthotics and supplies accounting for 9.7%. A small number of physicians continue to drive much of the IMR activity, as the top 1% of requesting physicians (81 doctors) accounted for 42.2% of the disputed service requests that underwent IMR in the 12 months ending on March 30 of this year, and the top 10 individual physicians accounted for 10.9% of the disputed requests. CWCI found that 7 of the providers on the latest top 10 list were also on the top 10 list the prior year. IMR outcomes remain stable, as IMR physicians upheld 89.1% of UR doctors' treatment modifications or denials in the first quarter of 2025 compared to 88.0% in 2024. As in the past, uphold rates varied by type of service, ranging from 77.4% for evaluation/management services to 92.9% for acupuncture. CWCI members and subscribers will find a more detailed summary of IMR experience through March 2025 in Bulletin 25-09 at Institute members can also access updated IMR slides under the Research tab.
Business Wire
34 minutes ago
- Business Wire
Mannatech Announces Promotion of Peter Griscom to Chief Operating Officer
FLOWER MOUND, Texas--(BUSINESS WIRE)-- Mannatech, Incorporated (NASDAQ: MTEX) announces the promotion of Peter Griscom to Chief Operating Officer of Mannatech Incorporated (the "Company") effective July 1, 2025. Peter Griscom brings more than 10 years of experience in the direct selling channel and has extensive experience in working in the consumer goods space, including launching, leading, and restructuring companies while creating efficiencies in manufacturing, sales, and marketing. Prior to his promotion, Mr. Griscom served as the Company's senior vice president of global operations since August 21, 2024 and prior to that served as the senior vice president of product, innovation, & supply chain from July 3, 2023 through August 20, 2024. He holds a B.S. from the University of Auburn and an M.S. from the University of Utah. Commenting on Mr. Griscom's promotion, Landen Fredrick, the Company's President and CEO stated, 'Peter's drive and determination to create operational efficiencies and streamline processes are instrumental in reducing costs and moving the Company forward. Elevating Peter to this new role will have a positive impact on the Company's future.' About Mannatech: Mannatech is a leading global health and wellness company committed to empowering everyone to live their best life through cutting-edge, science-backed nutritional products, patented technology, and a rewarding business opportunity. With operations in more than 25 markets †, Mannatech helps people to live healthier, more fulfilling lives while making a positive social impact in the world. Individuals interested in Mannatech's products or in exploring its business opportunity can learn more at Please Note: This release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as 'may,' 'will,' 'should,' "hope," 'could,' 'would,' 'expects,' 'plans,' 'intends,' 'anticipates,' 'believes,' 'estimates,' 'approximates,' 'predicts,' 'projects,' 'potential,' and 'continues' or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech's objectives, strategies, plans, goals, or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, the impact of COVID-19 on Mannatech's business, Mannatech's inability to attract and retain associates and members, increases in competition, litigation, regulatory changes, and its planned growth into new international markets. Although Mannatech believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.
Business Wire
38 minutes ago
- Business Wire
ExaGrid與Cohesity擴大合作，推出全新認證整合，為Cohesity NetBackup和DataProtect客戶提供無縫備份儲存解決方案
麻薩諸塞州馬爾伯勒--(BUSINESS WIRE)--(美國商業資訊)-- 全球最大的獨立備份儲存供應商 ExaGrid ®宣布其分層備份儲存產品線將成為 Cohesity DataProtect的歸檔儲存目標。 目前，ExaGrid已透過9項認證整合支援Cohesity NetBackup。作為Cohesity繼續服務於NetBackup和DataProtect客戶的一部分，ExaGrid的分層備份儲存設備將成為所有Cohesity客戶的歸檔儲存目標。 ExaGrid對Cohesity的支援預計將於2026年上半年正式啟動。 ExaGrid總裁暨執行長Bill Andrews表示：「我們很高興能夠為Cohesity提供支援，包括其NetBackup和DataProtect客戶。我們的客戶遍布80多個國家，他們皆對Cohesity興趣濃厚，我們希望能確保他們在ExaGrid上的投資在過渡期間仍然受到保護。」 ExaGrid分層備份儲存系統採用獨特架構，前端設有快速歸檔與復原的著陸區，後端配備安全儲存層，實現成本高效的重複資料刪除儲存。該系統單次部署可擴充至6PB，這是同類產品內建重複資料刪除功能的最大容量。在過去三年間，ExaGrid在備份儲存領域獲得的行業獎項數量超過所有其他供應商。 Cohesity產品長Vasu Murthy表示：「客戶依賴我們保護其資訊科技環境中數百艾位元組的關鍵客戶資料。Cohesity對資料來源和儲存目標的廣泛支援滿足了客戶的實際需求。我們很榮幸與ExaGrid合作，為尋求分層歸檔儲存解決方案的共同客戶提供支援。」 關於ExaGrid ExaGrid提供分層備份儲存產品，具有獨特的磁片快取著陸區、長期保留儲存庫、水平擴展架構和全面的安全特性。ExaGrid的著陸區可實現超快的備份和還原速度以及即時虛擬機器恢復。儲存庫層極大降低了長期保留成本。ExaGrid的水平擴展架構包括全套裝置，並確保隨著資料的成長提供固定備份期限，從而避免成本高昂的全面性大規模升級和計畫中的產品過時淘汰。ExaGrid提供獨有的兩層備份儲存方法，且具有非針對網路的分層（分層氣隙）、延遲刪除和不可變對象，可協助從勒索軟體攻擊中恢復。 ExaGrid在以下國家／地區擁有實體銷售及售前系統工程師：阿根廷、澳洲、比荷盧、巴西、加拿大、智利、獨立國協、哥倫比亞、捷克共和國、法國、德國、中國香港、印度、以色列、義大利、日本、墨西哥、北歐、波蘭、葡萄牙、卡達、沙烏地阿拉伯、新加坡、南非、韓國、西班牙、土耳其、阿拉伯聯合大公國、英國、美國及其他地區。 造訪我們，請前往 或透過 LinkedIn 與我們聯絡。看看我們的客戶親身體驗 ExaGrid 的評價，並瞭解為什麼他們目前花費在備份存儲上的時間大幅減少 客戶成功案例 。ExaGrid 為我們的 +81 NPS 分數深感自豪！ ExaGrid是ExaGrid Systems, Inc的註冊商標。所有其他商標均為各自持有人的財產。 免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。
